Clinical Trial Update: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immune response of an intranasal nanoemulsion-adjuvanted recombinant pandemic influenza vaccine in healthy adults; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• Intranasal nanoemulsion adjuvanted recombinant pandemic influenza vaccine

Snippet

Sponsor: BlueWillow Biologics | Conditions: Influenza, Pandemic | Phase 1 | Status: COMPLETED